109170 ⎘
Structure or type of the nucleic acid; Chemical structure of the sugar 2'-O-R Modification
Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT)
#2702Aptamer therapeutics useful in the treatment of complement-related disorders
#2703Short interfering ribonucleic acid (siRNA) for oral administration
#2704Genetic inhibition by double-stranded RNA
#2705Cell permeable nanoconjugates of shell-crosslinked knedel (SCK) and peptide nucleic acids (“PNAs”) with uniquely expressed or over-expressed mRNA targeting sequences for early diagnosis and therapy of cancer
#2706MicroRNAs that regulate muscle cell proliferation and differentiation
#2707Antisense nucleic acids
#2708Oligonucleotides comprising alternating segments and uses thereof
#2709RNA sequence-specific mediators of RNA interference
#2710Targeted 2′-O-methylation of telomerase non-coding RNA
#2711Micro-RNA family that modulates fibrosis and uses thereof
#2712Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
#2713Compositions and their uses directed to huntingtin
#2714Compositions and methods for inhibiting expression of mutant EGFR gene
#2715TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO HGF
#2716Dual targeting siRNA agents
#2717Selective inhibition of polyglutamine protein expression
#2718RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)
#2719Compounds and methods for modulating expression of DGAT2
#2720Nuclease resistant double-stranded ribonucleic acid
#2721Antisense modulation of GCCR expression
#2722Reduced size self-delivering RNAi compounds
#2723Antisense modulation of GCGR expression
#2724Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1
#2725Compositions and methods for modulation of SMN2 splicing
#2726Interfering RNA molecules
#2727Oligomers
#2728siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
#2729Modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure
#2730Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4
#2731Compositions and methods for inhibiting expression of CD45 gene
#2732MODULATION OF GLUCOSE-6-PHOSPHATASE TRANSLOCASE EXPRESSION
#2733Cationic lipids for oligonucleotide delivery
#2734Modulation of growth hormone receptor expression and insulin-like growth factor expression
#2735Selective reduction of allelic variants
#2736Inhibitors of FAM3B gene, inhibitor compositions, inhibiting methods and applications of inhibitors in preparing pharmaceuticals
#2737Double-stranded oligonucleotides
#2738miR-150 for the treatment of blood disorders
#2739Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
#2740Lipid formulated dsRNA targeting the PCSK9 gene
#2741DOUBLE STRAND COMPOSITIONS COMPRISING DIFFERENTIALLY MODIFIED STRANDS FOR USE IN GENE MODULATION
#2742Oligonucleotide compounds comprising non-nucleotide overhangs
#2743Modulation of Hepatitis B virus (HBV) expression
#2744Anti-sense oligonucleotides targeted against exon 9 of IL-23Rα gene and method of using same to induce exon skipping and to treat inflammatory bowel diseases
#2745Modulation of forkhead box O1A expression
#2746Genetic Inhibition by Double-Stranded RNA
#2747DOSING REGIMENS FOR TREATING AND PREVENTING OCULAR DISORDERS USING C-RAF ANTISENSE
#2748Compositions and methods for inhibiting expression of XBP-1 gene
#2749Modulation of angiopoietin-like 3 expression
#2750Compositions and methods for inhibiting expression of Eg5 and VEGF genes
#2751MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposes
#2752RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#2753Compositions and methods for inhibiting expression of GSK-3 genes
#2754Organic compositions to treat Beta-ENaC-related diseases
#2755GNAQ targeted dsRNA compositions and methods for inhibiting expression
#2756RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#2757Compositions and methods for inhibiting gene expression of hepatitis B virus
#2758Methods and compositions for reducing viral genome amounts in a target cell
#2759Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF
#2760Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
#2761Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
#2762Aptamer therapeutics useful in the treatment of complement-related disorders
#2763Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
#2764TRPM-2 antisense therapy
#2765Compositions and methods for inhibiting expression of the HAMP gene
#2766COMPOSITIONS AND THEIR USES DIRECTED TO IL-4R ALPHA
#2767MODULATION OF APOLIPOPROTEIN(A) EXPRESSION
#2768AGENTS, COMPOSITIONS AND METHODS FOR TREATING PATHOLOGIES IN WHICH REGULATING AN ACHE-ASSOCIATED BIOLOGICAL PATHWAY IS BENEFICIAL
#2769Targeting microRNAs for the treatment of liver cancer
#2770Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
#2771Modulation of glucagon receptor expression
#2772Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
#2773TREATMENT OF FILAGGRIN (FLG) RELATED DISEASES BY MODULATION OF FLG EXPRESSION AND ACTIVITY
#2774Proinflammatory nucleic acids
#2775Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR)
#2776TREATMENT OF INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO IRS2 AND TRANSCRIPTION FACTOR E3 (TFE3)
#2777Antisense modulation of PTP1B expression
#2778Synthetic mimics of miR-34
#2779Modulating Gene Expression With agRNA and Gapmers Targeting Antisense Transcripts
#2780Method of inhibiting miR-33 using a modified oligonucleotide
#2781Modulation of eIF4E expression
#2782Sirna compounds comprising terminal substitutions
#2783Modulation of signal transducer and activator of transcription 3 (STAT3)expression
#2784MicroRNA-10 antagonists and MicroRNA-10 targets for use in the treatment of a glioma
#2785Synthetic mimics of MIR-124
#2786MODULATION OF TTC39 EXPRESSION TO INCREASE HDL
#2787Antisense molecules and methods for treating pathologies
#2788Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1
#2789Duplex oligonucleotides with enhanced functionality in gene regulation
#2790Delivery System and Conjugates For Compound Delivery Via Naturally Occurring Intracellular Transport Routes
#2791Oligonucleotide complex compositions and methods of use as gene alteration tools
#2792Modulation of huntingtin expression
#2793RNAi modulation of APOB and uses thereof
#2794Minor groove binder (MGB)-oligonucleotide miRNA antagonists
#2795RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis
#2796Antisense oligonucleotides for inhibition of microRNA-21
#2797Compositions and methods for prognosis and treatment of prostate cancer
#2798Compositions and methods for inhibiting expression of transthyretin
#2799AGENTS USEFUL IN TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
#2800Process for triphosphate oligonucleotide synthesis
#2801MODIFIED DOUBLE-STRANDED POLYNUCLEOTIDE
#2802Methods for slowing familial ALS disease progression
#2803MODULATION OF FACTOR 7 EXPRESSION
#2804METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE
#2805COMPOSITIONS AND METHODS FOR THE MODULATION OF JNK PROTEINS
#2806COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF GCGR
#2807Compositions and methods for inhibiting expression of factor VII gene
#2808COMPOSITION FOR SUPPRESSING EXPRESSION OF TARGET GENE
#2809Antisense oligonucleotide modulation of STAT3 expression
#2810RNAi probes targeting cancer-related proteins
#2811Antisense oligonucleotides
#2812MODULATION OF SGLT-2 EXPRESSION
#2813ANTISENSE OLIGONUCLEOTIDES AGAINST ACETYLCHOLINESTERASE FOR TREATING INFLAMMATORY DISEASES
#2814Compositions and methods for modulation of SMN2 splicing in a subject
#2815ANTIVIRAL OLIGONUCLEOTIDES
#2816Compositions and methods for silencing apolipoprotein C-III expression
#2817ANTISENSE INHIBITION VIA RNASE H-INDEPENDENT REDUCTION IN MRNA
#2818Lipid formulation
#2819MicroRNA-24
#2820RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
#2821Method for modulating responsiveness to steroids
#2822Exon Skipping Therapy for Functional Amelioration of Semifunctional Dystrophin in Becker and Duchenne Muscular Dystrophy
#2823In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
#2824Chemical modification of short small hairpin RNAs for inhibition of gene expression
#2825Compositions and methods for inhibiting expression of RRM2 genes
#2826Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#2827Therapeutic uses of inhibitors of RTP801
#2828MODULATION OF EIF4E-BP2
#2829ANTISENSE OLIGONUCLEOTIDE MODULATION OF RAF GENE EXPRESSION
#2830MODULATION OF TRANSTHYRETIN EXPRESSION
#2831CHEMICAL MODIFICATIONS MOTIFS FOR MIRNA INHIBITORS AND MIMETICS
#2832SOLUBLE THF RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE
#2833Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP
#2834Methods for treating chronic kidney disease
#2835Compositions and Methods for Inhibiting Expression of Eg5 Gene
#2836ANTISENSE OLIGONUCLEOTIDES (ODN) AGAINST SMAD7 AND USES THEREOF IN MEDICAL FIELD
#2837Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin
#2838Organic compositions to treat HSF1-related diseases
#2839Organic compositions to treat HSF1-related diseases
#2840dsRNA for treating viral infection
#2841RNA targeting in alpha-synucleinopathies
#2842Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
#2843Organic compositions to treat Beta-ENaC-related diseases
#2844Targeting MicroRNAs for metabolic disorders
#2845Methods for enhancing utrophin production via inhibition of microRNA
#2846Long-Acting DNA Dendrimers and Methods Thereof
#2847Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#2848RNA sequence-specific mediators of RNA interference
#2849Treatment of neurological disorders
#2850Potent anti APOB antisense compounds
#2851Organic compositions to treat beta-ENaC-related diseases
#2852Organic compositions to treat Beta-ENaC-related diseases
#2853Modulation of STAT 6 expression
#2854COMPOSITIONS AND THEIR USES DIRECTED TO HEPCIDIN
#2855ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
#2856Oligomeric compounds and compositions for the use in modulation of target nucleic acids
#2857Anti-MicroRNA oligonucleotide molecules
#2858Modifications for Antisense Compounds
#2859Use of microrna-199b-5p in medical and diagnostic field
#2860Oligomers
#2861Oligomers
#2862THERAPEUTIC USES OF INHIBITORS OF RTP801L
#2863RNAi Modulation Of TGF-BETA And Therapeutic Uses Thereof
#2864DOUBLE-STRANDED OLIGONUCLEOTIDES
#2865SYNTHETIC METHODS AND DERIVATIVES OF TRIPHOSPHATE OLIGONUCLEOTIDES
#2866METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL DISEASES
#2867COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY NUCLEIC ACID CONTAINING A DICER SUBSTRATE AND A RECEPTOR BINDING REGION
#2868Compositions and methods for inhibiting expression of huntingtin gene
#2869METHODS OF MODULATING AN IMMUNE RESPONSE TO A VIRAL INFECTION
#2870Pharmaceutical Composition
#2871MODULATION OF INFLAMMATORY RESPONSES BY FACTOR XI
#2872Antisense modulation of C-reactive protein expression
#2873Methods for treating hypercholesterolemia
#2874Antisense modulation of PTP1B expression
#2875MicroRNA and methods for inhibiting same
#2876Nucleic acid chemical modifications
#2877Methods and compositions involving miRNA and miRNA inhibitor molecules
#2878Oligomers
#2879RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
#2880Lipids, lipid complexes and use thereof
#2881Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
#2882Inhibition of MAP4K4 through RNAI
#2883Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means
#2884Lipids and compositions for the delivery of therapeutics
#2885Treatment of neurological disorders by dsRNA administration
#2886Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1
#2887OLIGONUCLEOTIDE COMPRISING AN INOSINE FOR TREATING DMD
#2888TREATMENT OF TRISTETRAPROLINE (TTP) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TTP
#2889MicroRNAs In Idiopathic Pulmonary Fibrosis
#2890Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#2891Reduced size self-delivering RNAi compounds
#2892Method for inhibiting the activity of mir-155
#2893RNA sequence-specific mediators of RNA interference
#2894Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#2895Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#2896Antisense Oligonucleotides for Inducing Exon Skipping and Methods of Use Thereof
#2897Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#2898RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
#2899Short interfering ribonucleic acid (siRNA) for oral administration
#2900Short interfering ribonucleic acid (siRNA) for oral administration
#2901Antisense modulation of superoxide dismutase 1, soluble expression
#2902Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#2903Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#2904RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
#2905RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
#2906Compositions and methods for inhibiting expression of a gene from the JC virus
#2907Short interfering ribonucleic acid (siRNA) for oral administration
#2908Means for inhibiting the expression of ANG2
#2909Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA
#2910ANTISENSE MODULATION OF CHOLESTERYL ESTER TRANSFER PROTEIN EXPRESSION
#2911Compositions and methods for inhibiting expression of mutant EGFR gene
#2912RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
#2913RNA Interference Mediated Inhibition of BTB and CNC Homology 1, Basic Leucine Zipper Transcription Factor 1 (BACH1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
#2914Optimized Methods For Delivery Of DSRNA Targeting The PCSK9 Gene
#2915Compositions And Methods For Increasing Cellular Uptake Of RNAi Via SID-1
#2916COMPOSITIONS FOR INHIBITING GENE EXPRESSION AND USES THEREOF
#2917RNA sequence-specific mediators of RNA interference
#2918RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
#2919METHODS AND COMPOSITIONS FOR REPROGRAMMING CELLS
#2920RNA Interference Mediated Inhibition of the Intercellular Adhesion Molecule 1 (ICAM-1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
#2921RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
#2922RNA interference mediated inhibition of the FCεR1α gene
#2923Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
#2924TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#2925SNPs of apolipoprotein B and modulation of their expression
#2926METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
#2927Oligomeric compounds and methods
#2928Modulation of exon recognition in pre-mRNA by interfering RNA structure
#2929Compositions and their uses directed to huntingtin
#2930RNA interference mediating small RNA molecules
#2931RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#2932RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#2933LIPIDS, LIPID COMPLEXES AND USE THEREOF
#2934Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference
#2935MODULATION OF TRANSTHYRETIN EXPRESSION
#2936Means and methods for counteracting muscle disorders
#2937USE OF MIR-126 FOR ENHANCING HEMATOPOIETIC STEM CELL ENGRAFTMENT, FOR ISOLATING HEMATOPOIETIC STEM CELLS, AND FOR TREATING AND MONITORING THE TREATMENT OF ACUTE MYELOID LEUKEMIA
#2938ANTAGONISTS OF MIR-155 FOR THE TREATMENT OF INFLAMMATORY LIVER DISEASE
#2939RNA sequence-specific mediators of RNA interference
#2940SIRNA COMPOUNDS AND METHODS OF USE THEREOF
#2941RNA Interference Mediated Inhibition of Epithelial Sodium Channel (ENaC) Gene Expression Using Short Interfering Nucleic Acid (siNA)
#2942RNA sequence-specific mediators of RNA interference
#2943Compositions and methods for inhibiting expression of the HAMP gene
#2944Spinal muscular atrophy treatment via targeting SMN2 catalytic core
#29452'-F MODIFIED RNA INTERFERENCE AGENTS
#2946Gene Silencing by Single-Stranded Polynucleotides
#2947ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
#2948Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
#2949RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#2950METHODS AND MEANS FOR EFFICIENT SKIPPING OF AT LEAST ONE OF THE FOLLOWING EXONS OF THE HUMAN DUCHENNE MUSCULAR DYSTROPHY GENE: 43, 46, 50-53
#2951Organic compositions to treat beta-ENaC-related diseases
#2952Reduced size self-delivering RNAi compounds
#2953Methods of modulating mesenchymal stem cell differentiation
#2954Delivery of agents using interfering nanoparticles
#2955RNAi-related inhibition of TNFα signaling pathway for treatment of ocular angiogenesis
#2956Method of Treating Neurodegenerative Disease
#2957RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
#2958Compositions and methods for inhibition of nucleic acids function
#2959NOVEL siRNAS AND METHODS OF USE THEREOF
#2960Compositions and methods for inhibiting expression of CD274/PD-L1 gene
#2961METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE
#2962Targeting MicroRNAs For The Treatment Of Liver Cancer
#2963Method for generating aptamers with improved off-rates
#2964Nuclease resistant double-stranded ribonucleic acid
#2965RNA sequence-specific mediators of RNA interference
#2966RNA sequence-specific mediators of RNA interference
#2967RNA sequence-specific mediators of RNA interference
#2968MODIFIED OLIGORIBONUCLEOTIDE ANALOGS WITH ENHANCED IMMUNOSTIMULATORY ACTIVITY
#2969RNA interference in skin indications
#2970Neutral nanotransporters
#2971SPLICE SWITCHING OLIGOMERS FOR TNF SUPERFAMILY RECEPTORS AND THEIR USE IN TREATMENT OF DISEASE
#2972dsRNA COMPOSITIONS AND METHODS FOR TREATING HPV INFECTION
#2973Modulation of C-reactive protein expression
#2974Oligoribonucleotide inhibitors of Nrf2 and methods of use thereof for treatment of cancer
#2975Compositions and methods for inhibiting expression of the PCSK9 gene
#2976MODIFIED sIRNA MOLECULES AND USES THEREOF
#2977Oligomeric compounds and compositions for use in modulation of small non-coding RNAS
#2978ANTISENSE MODULATION OF STEAROYL-COA DESATURASE EXPRESSION
#2979ENHANCED ANTISENSE OLIGONUCLEOTIDES
#2980Modulation of gene expression by oligomers targeted to chromosomal DNA
#2981Therapeutic compositions
#2982Compositions and methods for inhibiting expression of a gene from the ebola virus
#2983Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases
#2984Compositions and methods for silencing Ebola virus gene expression
#2985Nuclease resistant external guide sequences for treating inflammatory and viral related respiratory diseases
#2986Compositions and methods for silencing apolipoprotein B
#2987RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
#2988RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF MACULAR EDEMA
#2989COMPOSITIONS COMPRISING CMYC SIRNA AND METHODS OF USE THEREOF
#2990Modulation of HIF1α and HIF2α expression
#2991Methods and means for treating DNA repeat instability associated genetic disorders
#2992RNAi modulation of SCAP and therapeutic uses thereof
#2993Compositions And Methods For Inhibiting Expression Of GSK-3 Genes
#2994Inhibition of angiogenesis
#2995Modulation of HSP47 expression
#2996METHODS FOR MODULATING EXPRESSION OF CREB
#2997MODULATION OF TRANSFORMING GROWTH FACTOR-BETA 1 EXPRESSION
#2998Minor groove binder (MGB)-oligonucleotide miRNA antagonists
#2999Conjugates For Use In Hepatocyte Free Uptake Assays
#3000Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (IRO) antagonists of TLR7 and TLR9